Great read here Timing. It really is sad how much faith we all had in Charles (Many of us never thought he would turn out to be typical OTC CEO), how much promise and potential, etc....
Unfortunately, the way I interpret all of this is that Charles is no different from other OTC CEO's, especially when it comes to his commons shareholders. He, Chandra, Joseph, etc.... got their 2.5M SAGA shares, and in typical OTC fashion, it appears he's dropping nothing but crumbs for us commons, but only after he coverts/dilutes us to death. Personally, I think he views us as nobodies and/or just penny investors (Yes, some of us got this cheap before the bioclonetics merger, but there are also many who invested 6 figures in this after the merger when it was priced much higher), and therefore has no interest in actually taking care of commons. As per normal in OTC, smaller commons and those who purchased much higher are the ones who are really getting screwed over.
Unfortunately, due to his silence, "bait & switch strategy" (#Audited, #Uplist, #SEC Reporting, #Parnterships, #Licensing, #Yachts, etc...., vs end of 2023 and still no audit, no SEC Reporting, no uplist, no ENZC licensing, and finally top it off by dropping PR which states that instead, they will be selling 99% of the value we've been holding for to some bottom of barrel SPAC, and subtlety drop in that ENZC will continue trading on pinks with no assets or operations ) I believe it will take an act of God for him to actually give some clarity on everything going on. Regardless of what anyone else thinks, that was more than a complete 180 on the strategy, that really stuck it to us.
Disappointing to say the least.
